Diagnostics
Molecular biomarkers hold great promise for diagnosing diseases at earlier, more treatable stages, but their full potential has not yet been realized. We are changing that paradigm by combining powerful molecular biology, chemistry, and engineering tools, for example, enabling biomarker detection down to the single-molecule level, both in the lab and at the point-of-care.
Some of these technologies are developed in partnership with Brigham and Women's Hospital through the Wyss Diagnostics Accelerator.